468 related articles for article (PubMed ID: 30115065)
1. Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis.
Choi HCW; Jit M; Leung GM; Tsui KL; Wu JT
BMC Med; 2018 Aug; 16(1):127. PubMed ID: 30115065
[TBL] [Abstract][Full Text] [Related]
2. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China.
Mo X; Gai Tobe R; Wang L; Liu X; Wu B; Luo H; Nagata C; Mori R; Nakayama T
BMC Infect Dis; 2017 Jul; 17(1):502. PubMed ID: 28720082
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
5. Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.
Choi HCW; Leung K; Chan KKL; Bai Y; Jit M; Wu JT
BMC Med; 2023 Feb; 21(1):48. PubMed ID: 36765349
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS
BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694
[TBL] [Abstract][Full Text] [Related]
7. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
9. National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States.
Durham DP; Ndeffo-Mbah ML; Skrip LA; Jones FK; Bauch CT; Galvani AP
Proc Natl Acad Sci U S A; 2016 May; 113(18):5107-12. PubMed ID: 27091978
[TBL] [Abstract][Full Text] [Related]
10. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
11. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
Boiron L; Joura E; Largeron N; Prager B; Uhart M
BMC Infect Dis; 2016 Apr; 16():153. PubMed ID: 27084683
[TBL] [Abstract][Full Text] [Related]
12. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
Jit M; Brisson M; Portnoy A; Hutubessy R
Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.
Phua LC; Choi HCW; Wu J; Jit M; Low J; Ng K; Pearce F; Hall C; Abdul Aziz MI
Vaccine; 2021 Apr; 39(16):2255-2263. PubMed ID: 33744050
[TBL] [Abstract][Full Text] [Related]
16. Knowledge, attitude, practice and barriers on vaccination against human papillomavirus infection: a cross-sectional study among primary care physicians in Hong Kong.
Wong MC; Lee A; Ngai KL; Chor JC; Chan PK
PLoS One; 2013; 8(8):e71827. PubMed ID: 23990994
[TBL] [Abstract][Full Text] [Related]
17. Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong.
Cheung TH; Cheng SSY; Hsu D; Wing-Lei Wong Q; Pavelyev A; Sukarom I; Saxena K
Hum Vaccin Immunother; 2023 Aug; 19(2):2184605. PubMed ID: 37183965
[TBL] [Abstract][Full Text] [Related]
18. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
Burger EA; Portnoy A; Campos NG; Sy S; Regan C; Kim JJ
Int J Cancer; 2021 Feb; 148(4):932-940. PubMed ID: 32706907
[TBL] [Abstract][Full Text] [Related]
19. Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.
Setiawan D; Andrijono ; Hadinegoro SR; Meyta H; Sitohang RV; Tandy G; Perwitasari DA; Postma MJ
PLoS One; 2020; 15(3):e0230359. PubMed ID: 32203527
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.
Tay SK; Ngan HY; Chu TY; Cheung AN; Tay EH
Vaccine; 2008 Aug; 26 Suppl 12():M60-70. PubMed ID: 18945415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
